| | | |   | | | | By Ed Silverman Adobe In 2020, several drugmakers began limiting some discounts when hospitals bought medicines and then shipped them to contract pharmacies. Read More | | By Damian Garde Getty Images for Gabrielle's Angel Foundation Clay Siegall was arrested April 23 after police said he repeatedly shoved his wife to the ground during a late-night dispute. Read More | | By Jason Mast Adobe In an unusual two-page summary, regulators said doctors failed to provide adequate evidence of effectiveness of the drug, called fluvoxamine. Read More | | Sponsor content by ICON CLINICAL RESEARCH Early engagement and regulatory considerations for drug development by emerging biotechs Despite robust funding and government initiatives for the development of orphan drugs and personalized medicines, small emerging biotech companies are typically very lean on resources, lacking the infrastructure required to bring their innovation to the market. Download this whitepaper, and find out how to navigate the complexities of drug development as a small biotech organization. Gain insights into key considerations for forming successful partnerships, and learn more about why it's crucial to engage a regulatory strategist in all aspects of drug development. | | By Kate Sheridan Molly Ferguson for STAT The last time there was a big wave of biotech acquisitions, buyers snapped up early-stage companies much more often than usual. Read More | | By Ed Silverman APStock The Greek government is “taking all measures to hold Novartis accountable and compensate the Greek state for its illegal practices." Read More | | By Allison DeAngelis Adobe Sofinnova is the third major biopharma venture capital firm to make a private equity deal in the last seven months. Read More | |
No comments